A case of HIV co‐infected with hepatitis B virus precore/core deletion mutant treated by entecavir

We report a case of a HIV and hepatitis B virus (HBV)‐co‐infected patient to whom entecavir (ETV) was administered initially before the notification regarding the potential mutagenesis effect on HIV against the nucleoside analog. Since initial evaluations indicated the advanced stage of chronic hepatitis B and preserved numbers of peripheral CD4+ lymphocytes without the manifestation of immunodeficiency, priority was given to the management of HBV. We started HBV therapy with ETV at a dose of 0.5 mg daily without using any HIV drugs. The viral loads of both HBV and HIV‐1 decreased gradually during the 5 months following the initial administration of ETV. HBV was well controlled by the gradual replacement of ETV with highly‐active antiretroviral therapy against HIV with a regimen including atazanavir, emtricitabine, and tenofovir. HBV was genotyped as A2 with the quasispecies pool consisting of the −1G precore/core deletion mutant strain.

[1]  S. Lewin,et al.  Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals , 2007, AIDS.

[2]  W. Sugiura,et al.  Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. , 2007, Antiviral research.

[3]  Lin Shen,et al.  The HBV drug entecavir - effects on HIV-1 replication and resistance. , 2007, The New England journal of medicine.

[4]  FDA notifications. Entecavir revision made by FDA and BMS. , 2007, AIDS alert.

[5]  C. Mazzucco,et al.  Entecavir resistance is rare in nucleoside naïve patients with hepatitis B , 2006, Hepatology.

[6]  M. Sata,et al.  Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  G. Kristiansen,et al.  Functional analysis of complex hepatitis B virus variants associated with development of liver cirrhosis. , 2006, Gastroenterology.

[8]  R. Ueda,et al.  Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection , 2006, Hepatology.

[9]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[10]  R. Rathbun,et al.  Current HIV treatment guidelines--an overview. , 2006, Current pharmaceutical design.

[11]  Y. Benhamou.  Treatment algorithm for chronic hepatitis B in HIV-infected patients. , 2006, Journal of hepatology.

[12]  T. Nishizawa,et al.  Characterization of seven genotypes (A to E, G and H) of Hepatitis B virus recovered from Japanese patients infected with human immunodeficiency virus type 1 , 2005, Journal of medical virology.

[13]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[14]  N. Shire,et al.  Management of HBV/HIV-coinfected Patients. , 2005, Seminars in liver disease.

[15]  J. Sasadeusz,et al.  Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  T. Nishizawa,et al.  High Prevalence of Antibodies to Hepatitis A and E Viruses and Viremia of Hepatitis B, C, and D Viruses among Apparently Healthy Populations in Mongolia , 2004, Clinical Diagnostic Laboratory Immunology.

[17]  J. Gerberding,et al.  Morbidity and Mortality Weekly Report Inside: Continuing Education Examination Applying Public Health Strategies to Primary Immunodeficiency Diseases a Potential Approach to Genetic Disorders Centers for Disease Control and Prevention Epidemiology Program Office Recommendations and Reports 1 Applyin , 2022 .

[18]  C. Tural,et al.  Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations , 2004, Journal of viral hepatitis.

[19]  Acip.  Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2004 .

[20]  Yoshiyuki Suzuki,et al.  The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. , 2003, Journal of hepatology.

[21]  T Ichida,et al.  Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan , 2001, Hepatology.

[22]  S. Günther,et al.  Enhanced replication contributes to enrichment of hepatitis B virus with a deletion in the core gene. , 2000, Virology.

[23]  R. Colonno,et al.  Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus , 1997, Antimicrobial agents and chemotherapy.